Suchergebnisse - "Rejeski, Kai"

PubPharm (7)

1

Recognizing, defining, and managing CAR-T hematologic toxicities

enthalten in: Hematology. American Society of Hematology. Education Program | 2023

von Rejeski, K. | Subklewe, M. | Locke, F.

2

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

enthalten in: Blood advances | 2023

von Blumenberg, V. | Busch, G. | Baumann, S. | +24

3

In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer

enthalten in: Oncoimmunology | 2023

von Xu, T. | Karschnia, P. | Cadilha, B. | +22

4

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

enthalten in: Blood | 2022

von Rejeski, K. | Wu, Z. | Blumenberg, V. | +11

5

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies

enthalten in: Haematologica | 2022

von Dos Santos, D. | Rejeski, K. | Winkelmann, M. | +10

6

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells

enthalten in: Neurology | 2022

von Karschnia, P. | Rejeski, K. | Winkelmann, M. | +10

7

CAR-HEMATOTOX : a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

enthalten in: Blood | 2021

von Rejeski, K. | Perez, A. | Sesques, P. | +24

CommentIn: Blood. 2021 Dec 16;138(24):2447-2448. - PMID 34914831

1
[1]